Meet our network

When you join our curated community you can meet and work with our network of thought leaders, innovators, and industry experts. Our network is focused on entrepreneurship and the world of life science. The constant interaction across disciplines within this ecosystem stimulates new ways of thinking, producing solutions that redefine and vitalize our reality.

meet our start-ups

Our diverse community of founders in the heart of Göttingen is steadily growing. Read on to learn more about them – their stories, their successes, and their challenges. This is where entrepreneurship and scientific inquiry come together, enriching our collaborative community every day.

Cultimate Foods

Cultimate Foods creates a game-changing ingredient based on cultivated fat in a sustainable and ethical way.
Their unique solution enriches plant-based meat alternatives with authentic taste, mouthfeel, and texture. They believe that the future of meat is hybrid – a combination of plant-based proteins and their fat alternative product.

Find out more


Globally, water-borne bacterial infections lead to half a million diarrhoeal-related deaths each year—more than 2,000 deaths every day. This is more than malaria and HIV-related deaths combined. WaterScope seeks to overcome global water inequality by breaking barriers to reliable bacterial testing. The team has developed an innovative testing device that can reliably and automatically identify bacterial presence in water in as little as 18 hours. The testing data is provided in real time and is uploaded to a central dashboard, connecting users in over 165 countries around the world.

Find out more

Ucaneo Biotech

We are building the world’s first biotechnological Direct Air Capture (DAC) system with the goal to to capture 1% of the global CO2 emissions by 2035!

Leveraging novel membranes and enzymes significantly reduces the energy consumption by lowering the conventional Direct Air Capture reaction temperature from up to 900°C to room temperature and avoiding active air intake. This enables massive cost savings and a sustainable reduction of CO2 in the atmosphere. 

Using the most modern equipment and S1 lab as well as our makerspace we found the perfect place at the Life Science Factory to develop our biotech hardware solution.

find out more


About 50% of all therapies have a protein component, but therapeutic protein development is very expensive and takes 2-3 years. Cinference is a life-science biotech startup that designs therapeutic proteins. Cinference’s mission is to shorten the protein development process to 1-2 months. To do this, the company uses data-efficient algorithms in combination with large AI models trained on millions of protein sequences to perform 99% of the design process digitally and optimize design parameters simultaneously. The young startup is on a growth trajectory and is hiring more biology talent to work on its first pharma partnerships. Cinference plans to move into the Life Science Factory next March and use the newly built lab.

Find out more


Pramomolecular is a spin-off of TU Berlin and has two patented transport molecules that make it remarkably easy to introduce short interfering RNAs (siRNAs) into lung and pancreas cells. Theoretically, siRNAs can be used to switch off any pathogenic protein, provided that the siRNAs can be successfully introduced into the relevant cells. Up to now, using the currently available delivery systems this has functioned really well only in the liver and for local applications, e.g. in the eye.

Since it is relatively easy to rationally design and produce siRNAs, Pramomolecular has been able to take the risk of developing its own drug candidates. If the technique works as planned, the start-up will be able to develop its drug candidates, up to and including the first human trials, in half the time and for only one percent of the cost as compared to conventional “small-molecule” drugs. The goal is to enable use of siRNAs to address diseases considered “undruggable” by small-molecule drugs, such as pancreatic cancer.

Find out more

Curexsys GmbH – Pure to Cure

Curexsys is active in the anti-aging field and develops exosomes as innovative therapeutics to cure age-related diseases.

Curexsys is active in the anti-aging field and combats age-related defects with exosomes derived from induced mesenchymal stem cells (iMSCs).  Exosomes constitute a new therapeutic principle clearly distinct from classical small or large molecule compounds or cell therapy. They are small vesicles that are naturally released from a cell. They contain proteins, nucleic acids and metabolites, which carry information from secreting to receiving cells. Exosomes have immunomodulatory and anti-inflammatory effects.

Due to increasingly aging societies, anti-aging therapies are of great interest to the pharma industry, health care providers and aging populations, and the Curexsys exosome platform will serve the arising demand of pure and functional exosomes in pharma industry. With the leading technology for highly selective and traceless purification of extracellular vesicles with low-affinity Fabs, Curexsys uses a unique technology to generate products for clinical applications, matching medical needs with increasing patient numbers in multiple disease areas.

Find out more


YoniCore brings back the life quality for women with pelvic floor dysfunctions with an end to end treatment. The smart connected medical device offers immediate relief of the symptomes alongside training of the pelvic muscles over an app.

YoniCore brings back the confidence and life quality for women with pelvic floor dysfunctions, a disease that every second woman will suffer from during her lifetime. YoniCore’s smart connected medical device offers individualized treatment for every woman and her unique pelvic floor. The immediate relief of the symptomes is due to the biocompatible silicone device that supports the pelvic organs using soft robotic technology. Alongside the YoniCore’s app offering a fun training program for the pelvic muscles that is integrated in women’s daily routines. We help women to become more active towards their well being – up to a point that their pelvic floor is healed. For the first time in the world, women can get holistic treatment based on immediate relief for their symptoms and long-term training in an easy and fun way.

Find out more

OptoGenTech GmbH

OptoGenTech is striving to make a transformative improvement in hearing aids by developing an optogenetic cochlear implant. Electrical cochlear implants are used by more than one million people worldwide who are deaf or profoundly hearing impaired. These implants typically enable speech intelligibility in quiet, but their users still have great difficulty understanding speech in noisy environments and following melodies in speech or music.

The use of optogenetics – stimulation through light – has enabled OptoGenTech to improve frequency resolution in cochlear implants, because light can be confined in space better than electric current can. The market volume for cochlear implants is expected to reach USD 4.5bn by the time of OptoGenTech’s market launch, planned for 2029. Given the changing technology and the expected fundamental improvement in hearing quality, OptoGenTech expects optogenetic implants to attain a significant market share.

Find out more

VineForecast UG

Software for data-driven viticulture!

VineForecast is smart-farming software that uses artificial intelligence to help wine-growers manage their vineyards more efficiently.

Viticulture currently uses 25 times more fungicides per hectare than primary agriculture. This results in not only environmental pollution, but also undue expenditure of both time and money. With its AI-based prognoses of grapevine diseases and a wealth of farm management functions (task management, documentation, GPS-localized damage reporting, and more), VineForecast provides hard data as a basis for pest-management decisions and enables extensive automation of operations. This is how we – Paul Petersik (climate physicist), Max Nowack (software engineer) and Richard Petersik (business economist) – want to reduce the use of pesticides in viticulture to a minimum!

Mehr erfahren


Redesigning drug development by continuous real-time & high-content analysis
Redesigning drug development through continuous real-time & high-content analysis

myofarm aims to establish a multiparametric non-invasive measurement infrastructure that enables detailed long-term insight, independent of time and place, into the drug-induced interaction of the excitation-contraction coupling of miniaturized human myocardium. The measured data are accumulated in a machine-readable database structure for future in silico drug simulations. Users will be able to plan and carry out complex analyses, including long-term analyses, by accessing the automated high-content procedure without having to set up a physical measurement infrastructure on their own premises. In the long term, myofarm hopes to develop regulation-compliant processes to support pharmaceutical research in bringing new drugs to market maturity in a sustainable and time- and cost-effective manner while avoiding animal experimentation as far as possible.

Find out more

get in touch with our mentors

Get expert support from our mentors and investors. Especially in the early stages, start-ups need tailored support in meeting their challenges. Our experts are successful life science founders, investors, and scientists who are always eager to share their specific expertise to sustainably boost innovative projects. 

Dr. Grit Zahn

Head of Research at Eternygen GmbH I Drug Development, Company building, technology transfer

Grit is a biochemist and has been active in drug development for more than 20 years. She has held a number of positions at many institutions and companies, working as a researcher at the Charité university medical center in Berlin; in drug development at the Jerini AG biotech company where she helped develop a product to market maturity; in technology transfer at ipal GmbH; and today at Eternygen GmbH, where she is head of research and also advises other biotech companies.

LinkedIn Profil Grit Zahn

Magdalena Kempa

Managing Director & Venture Manager I Biotech Venture Building

Magdalena is an experienced managing director and venture manager for life science start-ups. As managing director of smartbax GmbH she is responsible for project management, teams, finance, business development, legal matters, and investor relations. As a venture manager at Blue Ribbon Partners for more than four years, she is well acquainted with the world of life science start-ups and scale-ups. Magdalena has been a consultant for venture teams and corporate incubation for more than 10 years.

LinkedIn Profil Magdalena Kempa

Valentin Christian Splett

Advisor & Entrepreneur I Go To Market & Sales Scale Up for Health Technology and Life Sciences Ventures

Valentin has held leading marketing, sales and consulting positions in biotechnology and medical technology in the USA, Switzerland, and Germany for 13 years, including CCO at Ability Switzerland AG, a medical-equipment spinoff of ETHZ. He is involved in more than 200 go-to-market and sales scale-up projects in the health tech and life science sectors. Moreover, Valentin is co-founder of a new company in orthopedic surgery, lecturer at the FHGR, and board member at visionary AG.

LinkedIn Profil Valentin Splett

learn more?

Then sign up for a community ticket and get access to the entire network.

shoutout to our partners!

Instagram Instagram Instagram

By displaying this Instagram feed you agree to Instagram’s use of cookies. This may include analytics, personalization and ads.

Learn more


Keep in touch!

As a part of our community, you will receive invitations to events and will be the first to obtain the latest updates. #nospam

By displaying this Google map you agree to Google’s use of cookies. This may include analytics, personalization and ads.

Learn more


    event application

    You need to load Google reCAPTCHA before sending the form.

    Google reCAPTCHA Privacy Policy

      Contact form

      No file selected

      You need to load Google reCAPTCHA before sending the form.

      Google reCAPTCHA Privacy Policy